FRED B. CRAVES - 16 Jun 2022 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Brian Lynch, as attorney-in-fact for Fred B. Craves, Ph.D.
Issuer symbol
MDGL
Transactions as of
16 Jun 2022
Transactions value $
$0
Form type
4
Filing time
21 Jun 2022, 06:30:21 UTC
Previous filing
02 Feb 2022
Next filing
20 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award $0 +9.47K $0.00 9.47K 16 Jun 2022 Common Stock 9.47K $65.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date.